Enveric Biosciences, Inc. (NASDAQ:ENVB – Get Free Report) saw a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 19,617 shares, a drop of 49.3% from the October 15th total of 38,702 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average daily trading volume, of 35,170 shares, the days-to-cover ratio is currently 0.6 days.
Enveric Biosciences Price Performance
Shares of NASDAQ:ENVB traded down $0.05 during trading on Monday, hitting $1.47. 28,408 shares of the company were exchanged, compared to its average volume of 1,242,881. The company has a market cap of $6.58 million, a PE ratio of -0.12 and a beta of 1.23. Enveric Biosciences has a 52-week low of $1.17 and a 52-week high of $13.25. The stock has a 50 day moving average of $1.47 and a 200 day moving average of $1.89.
Enveric Biosciences (NASDAQ:ENVB – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.57) earnings per share for the quarter.
Analyst Ratings Changes
View Our Latest Stock Report on ENVB
Institutional Inflows and Outflows
A hedge fund recently raised its position in Enveric Biosciences stock. StoneX Group Inc. boosted its position in shares of Enveric Biosciences, Inc. (NASDAQ:ENVB – Free Report) by 136.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,986 shares of the company’s stock after buying an additional 16,172 shares during the quarter. StoneX Group Inc. owned approximately 0.63% of Enveric Biosciences worth $41,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 13.82% of the company’s stock.
Enveric Biosciences Company Profile
Enveric Biosciences is a biotechnology company developing small-molecule treatments for mental health conditions. Its research focuses on neuroplastogens—compounds designed to promote changes in neural connections—with potential applications in disorders such as depression and anxiety. The company uses its Psybrary platform, a library of compounds inspired by psychedelic molecules, to identify and develop therapeutic candidates. Its programs are in development, and the company’s work is focused on research rather than marketed medicines.
Further Reading
- Five stocks we like better than Enveric Biosciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
